Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) will host a virtual investor and analyst event on December 8, 2025 at 12:30 PM ET / 9:30 AM PT to discuss data on the triplet combination of ziftomenib (KOMZIFTI) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia. The presentation covers results scheduled for the 67th ASH Annual Meeting. Management and lead investigators will participate. A live webcast and replay will be available on the company website under Investors > Events and Presentations.

Argus Dec 3 session

+7.55% close to close Open Argus

Details

News Market Reaction – KURA

In the Dec 3 session, KURA gained 7.55%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +7.5% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +7.5% in the session following this news. A strong positive reaction aligns with the pattern seen when Kura highlighted its ASH-related investor event, which previously saw a 7.55% gain. However, history also showed negative moves after favorable commercialization and data updates, suggesting enthusiasm sometimes faded quickly. Investors monitoring such a surge might have weighed ongoing ziftomenib news flow, insider sell-to-cover activity, and overall biotech volatility when assessing how durable the strength could be.

Key Figures

Event date: December 8, 2025 Event time ET: 12:30 PM ET Event time PT: 9:30 AM PT +1 more

Event date

December 8, 2025

Scheduled virtual analyst and investor event

Event time ET

12:30 PM ET

Start time for virtual investor event

Event time PT

9:30 AM PT

Start time for virtual investor event

ASH meeting number

67th

67th American Society of Hematology Annual Meeting

Historical Context

5 past events · Latest: Dec 08

5 events

1. Dec 08

   ASH combo data

   24h Move

   -2.6%

   Detailed ASH 2025 data on KOMZIFTI triplet in AML cohorts.

2. Dec 03

   Investor event notice

   24h Move

   +7.5%

   Announcement of Dec 8 virtual investor/analyst event on ASH data.

3. Dec 02

   First U.S. sale

   24h Move

   -2.7%

   First U.S. KOMZIFTI sale triggering $135M milestone payment.

4. Nov 25

   NCCN guideline add

   24h Move

   +3.4%

   KOMZIFTI added as Category 2A AML option in NCCN guidelines.

5. Nov 13

   FDA approval

   24h Move

   +0.0%

   FDA approval of KOMZIFTI for R/R NPM1-mutated AML patients.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

acute myeloid leukemia, relapsed/refractory

2 terms

acute myeloid leukemia medical

"triplet combination of ziftomenib (KOMZIFTI®) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia scheduled"

A fast‑moving blood cancer that starts in the bone marrow and crowd out healthy blood cell production, leaving the body short of normal red cells, white cells and platelets. It matters to investors because the disease creates urgent medical need, drives demand for new diagnostics and treatments, and so clinical trial results, regulatory decisions and drug pricing can rapidly change the commercial prospects and valuation of companies working on therapies.

relapsed/refractory medical

"with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia scheduled"

Relapsed/refractory describes a disease, usually cancer, that has returned after treatment (relapsed) or that did not respond to initial therapy (refractory). For investors this signals a high medical need and a defined patient group for new treatments — like a market of cars that won’t start with a standard key — which can affect drug development priorities, trial designs, potential pricing and commercial opportunity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Event Scheduled for December 8, 2025 at 12:30 PM ET

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual analyst and investor event on Monday, December 8, 2025, at 12:30 PM ET / 9:30 AM PT, to discuss data on the triplet combination of ziftomenib (KOMZIFTI^®) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia scheduled for presentation at the 67th American Society of Hematology (ASH) Annual Meeting.

The virtual event will feature members of the management team alongside lead investigators. The live webcast and replay will be available on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the Kura Oncology (KURA) virtual investor event to discuss ASH 2025 data?

The event is scheduled for December 8, 2025 at 12:30 PM ET / 9:30 AM PT.

What data will Kura Oncology (KURA) discuss at the December 8, 2025 webcast?

Data on the triplet combination of ziftomenib (KOMZIFTI) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory AML.

How can investors watch the Kura Oncology (KURA) ASH 2025 event webcast?

The live webcast and replay will be available on Kura Oncology’s website under Investors > Events and Presentations.

Who will present at the Kura Oncology (KURA) virtual analyst and investor event on December 8, 2025?

The presentation will feature members of management alongside the lead investigators for the ASH 2025 data.

What topic will Kura Oncology (KURA) cover from the 67th ASH Annual Meeting on December 8, 2025?

The company will discuss ASH 2025 results for the ziftomenib, venetoclax, and azacitidine triplet regimen in AML.